Probable predictive biomarkers for tumor reaction to mTOR inhibitors, as happen to be explained in glioblastoma, breast and prostate cancer cells, may be the differential expression of mTOR pathway proteins, PTEN, AKT, and S6.[one] Hence, this knowledge relies on preclinical assays, according to in vitro cultured tumor mobile traces, which counsel